ENDO 2025 Abstract
SUN-685 A comparison of the metabolic effects of a long-acting GIPR agonist versus a GIPR antagonist
Experiments in animalsInterventions
Related
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes